Tasso Secures $100M In Series B Financing
12/16/21, 1:03 PM
Location
seattleMoney raised
$100 million
Industry
mobile
health care
information technology
software
education
Round Type
series b
Tasso, Inc., a leader in clinical-grade blood collection technology, today announced that it has completed an oversubscribed $100 million Series B financing round, bringing the total funding to date to $131 million. The financing round was led by RA Capital Management and included participation from new investors the D.E. Shaw group, Senvest, InCube, and SVB Innovation Fund, as well as existing investors Foresite Capital, Hambrecht Ducera Growth Ventures, J2V, Cedars-Sinai, and Merck GHIF.
Company Info
Location
seattle, washington, united states
Additional Info
Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants from the Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, and the National Institutes of Health, by investments from RA Capital, the D.E. Shaw group, Senvest, InCube, SVB Innovation Fund, Hambrecht Ducera Growth Ventures, J2V, Merck Global Health Innovation Fund, Foresite Capital, Vertical Venture Partners, Techstars, and Cedars Sinai, and by co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.